Beruflich Dokumente
Kultur Dokumente
Patologik
Risk factors
Obstruction
When part of the airway (bronchi) leading to
the alveoli is obstructed, the lung is not able
to clear fluid when it accumulates. This can
lead to infection of the fluid resulting in
CAP.
Risk factors
Lung disease
People with underlying lung disease are
more likely to develop CAP.
Immune problems
People who have immune system problems
are more likely to get CAP.
Etiology
Most cases of CAP are caused by a few
common respiratory pathogens, including:
o Streptococcus pneumoniae
Accounts for ~50% of all cases of CAP requiring
hospital admission
o Haemophilus influenzae
o Staphylococcus aureus
o Mycoplasma pneumoniae
o Chlamydia pneumoniae
o Moraxella catarrhalis
o Legionella spp.
o Aerobic gram-negative bacteria
o Influenza viruses
o Adenoviruses
o Respiratory syncytial virus
History
o Most typical
signs/symptoms
Fever
Cough (nonproductive
or productive of purulent
sputum)
Pleuritic chest pain
Chills and/or rigors
Dyspnea
o Frequent
signs/symptoms
Headache
Nausea
Vomiting
Diarrhea
Fatigue
Arthralgia/myalgia
Falls and new-onset
or worsening confusion
(in elderly patients)
Physical
o
findings
Fever
o Tachypnea
In two studies, patients with
a respiratory rate of >25/min
had a pneumonia likelihood
ratio of 1.53.4.
o Tachycardia
Patients with a heart rate of
100/min, a temperature of
37.8C, and a respiratory rate
of 20/min were 5 times more
likely to have pneumonia than
patients without these findings
in one study.
o Chest examination
Dullness to percussion
Increased tactile and
vocal fremitus
Whispering pectoriloquy
Crackles
Pleural friction rub
CLASIFICATION
CLASIFICATION
ADJUNCT
PTENTIAL PATHOGEN
EMPIRIC THERAPY
Streptococcus
pneumoniae
Haemophilus influenzae
Chlamydophilia
pneumoniae
Mycoplasma
pneumoniae
Moraxella catarrhalis
Enteric Gram-negative
bacilli
(among those with comorbid
illness)
Previously healthy:
amoxicillin
OR
extended macrolides
Alternative:
cotrimoxazole
With stable comorbid
illness:
co-amoxiclav OR
sultamicillin
OR
2nd generation
cephalosporins
OR
extended macrolide
POTENTIAL
PATHOGEN
EMPIRIC THERAPY
Streptococcus
pneumoniae
Haemophilus influenzae
Chlamydophilia
pneumoniae
Mycoplasma
pneumoniae
Moraxella catarrhalis
Enteric Gram-negative
bacilli
Legionella pneumophila
Anaerobes (among those
with
risk of aspiration)
IV nonpseudomonal blactam
with or without blactamase
inhibitor + macrolide
OR
antipneumococcal
fluoroquinolones (FQ)
POTENTIAL
PATHOGEN
EMPIRIC THERAPY
Streptococcus
pneumoniae
Haemophilus influenzae
Chlamydophilia
pneumoniae
Mycoplasma
pneumoniae
Moraxella catarrhalis
Enteric Gram-negative
bacilli
Legionella pneumophila
Anaerobes (among those
with
risk of aspiration)
Staphylococcus aureus
Pseudomonas
aeruginosa
No risk for P.
aeruginosa:
a. IV nonpseudomonal
blactam
with or without
blactamase
inhibitor +
IV macrolide
b. IV antipneumococcal
FQ
With risk for P.
aeruginosa:
IV pseudomonal blactam with
or without b-lactamase
inhibitor
+
IV macrolide or
IV antipneumococcal FQ
+/aminoglycoside or
Indikasi Rawat
C confusion
U Blood Urea >7mmol/l (jadi BUN
19,6mg/dl)
R Respiratory Rate > 30x/mnt
B Blood Pressure S<90; D<60
65 Age > 65 years
Bila 2 kriteria rawat
> 3 kriteria rawat ICU
Diagnosa(1)
Diagnosa (2)